ALX, HAFC and HBNC made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 25, 2025.
Here is how Alexander's (ALX) and Banco Bilbao (BBVA) have performed compared to their sector so far this year.
ALX, HAFC and FHB made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 13, 2025.
ALX, VLY and HAFC made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 11, 2025.
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $4.06 per share, beating the Zacks Consensus Estimate of $3.71 per share. This compares to FFO of $4.99 per share a year ago.
Alexander's has dipped materially from its 52-week high following a spike in the US 10-year Treasury yield. The REIT generated fiscal 2024 third-quarter FFO of $2.84 per share, down from its year-ago comp. A $354.8 million cash and cash equivalents position helps to provide a buffer for the REIT, but 2025 debt maturities are heavy and will pose a challenge.
Alexander's, Inc. has underperformed since 2019, with a -1.7% TSR compared to SPY's 113%, due to declining profitability and rich valuations. Despite increasing NOPAT since 2020, the Company's GAAP net income and NOPAT margins have declined from 2019 highs, impacting overall profitability. Management has created value with $154 million in economic earnings since 2019, but ALX remains overvalued with unrealistic growth expectations.
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $2.84 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to FFO of $3.63 per share a year ago.
ALX, JSAIY and NBTB made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 18, 2024.
SN, ALX, BPOP, ARCAY and JSAIY have been added to the Zacks Rank #1 (Strong Buy) List on September 18, 2024.
BANF, ALX and BPRN made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 13, 2024.
ALX Oncology's Evorpacept, a first-in-class CD47 inhibitor, shows promising results in cancer treatment with reduced side effects and a favorable safety profile. Evorpacept's combination with TRP demonstrated improved response rates and longer duration of response in HER2-positive gastric and GEJ cancer trials. The ASPEN-06 trial also showed favorable results, with a 40.3% ORR in HER2-positive gastric/GEJ cancer, higher than the control group's 26.6%.